Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma

  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Tian, Guang-Yu (Department of Oncology, JiangDu People's Hospital of Yangzhou) ;
  • Cao, Jie (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Xu, Xia (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Lu, Yan-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Liu, Jin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Shi, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Xiang, Jin (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2013.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The current research was conducted to investigate the efficacy and safety of pemetrexed given continuously as a basement agent for first-, second- to third line chemotherapy of patients with metastatic lung adenocarcinoma. Patients and Methods: Patients with metastatic lung adenocarcinoma who were diagnosed in Jiangsu Cancer Hospital and Research Insitute, were enrolled. All received pemetrexed 500 $mg/m^2$ (intravenous; on day 1), and another chemotherapieutic agent every 3 weeks until disease progression, or intolerable toxicity. Then the patients were changed to a second line chemotherapy that was still based on pemetrexed 500 $mg/m^2$ and another chemotherapeutic agent differing from the first line example, until disease progression, or intolerable toxicity. When third line chemotherapy was needed, pemetrexed 500 $mg/m^2$ and another new chemotherapeutic agent were combined until disease progression. Evaluation of efficacy was conducted after two cycles of chemotherapy using the Response Evaluation Criteria for Solid Tumors. Toxicity was recorded according to NCI Criteria for Adverse Events version 3.0. Results: From January 2010 to September 2013, 15 patients were enrolled. Their median age was 56 years (range 43 to 77 years). Eight patients were male and 7 female. Five patients (33.3%) achieved PR, while 6 patients (40.0%) remained stable, no CR on first line; and 1 PR (7.7%), 5 stable (38.5%) were recorded when pemetrexed was ordered in second line; 5 patients (41.7%) were stable after pemetrexed was combined in third line; no complete response was observed. Main side effects were grade 1 to 2 neutrophil suppression and thrombocytopenia. Other toxicities included elevated transaminase and oral mucositis, but no treatment related death occurred. Conclusions: Pemetrexed continuously as a basement agent from first-, second- to third line chemotherapy is mildly effective in treating patients with metastatic lung adenocarcinoma with tolerable toxicity.

Keywords

References

  1. Adjei AA (2004). Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res, 10, S4276-80. https://doi.org/10.1158/1078-0432.CCR-040010
  2. Ajani JA (2005). Evolving chemotherapy for advanced gastric cancer. Oncologist, 10, 49-58. https://doi.org/10.1634/theoncologist.10-90003-49
  3. Bajetta E, Celio L, Buzzoni R, et al (2003). Phase II study of pemetrexed disodium (alimta ) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol, 14, 1543-8. https://doi.org/10.1093/annonc/mdg406
  4. Celio L, Buzzoni R, Longarini R, et al (2002). Pemetrexed in gastric cancer: clinical experience and future perspectives. Semin Oncol, 29, 63-8. https://doi.org/10.1053/sonc.2002.37475
  5. Celio L, Sternberg CN, Labianca R, et al (2009). Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol, 20, 1062-7. https://doi.org/10.1093/annonc/mdn766
  6. Chen JS, Chao Y, Bang YJ et al (2010). A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anticancer Drugs, 21, 777-84. https://doi.org/10.1097/CAD.0b013e32833cfbca
  7. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  8. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  9. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 873-5. https://doi.org/10.7314/APJCP.2012.13.3.873
  10. Gu M, Li SY, Huang XE, et al (2013). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91.
  11. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  12. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  13. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.Asian Pac J Cancer Prev, 11, 1059-62.
  14. Karpeh MS, Kelsen DP, Tepper JE (2001). Cancer of the stomach. In DeVita VTJr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott, Williams and Wilkins, 1092-126.
  15. Kim JH, Lee KW, Jung Y, et al (2005), Cytotoxic effects of pemetrexed in lung adenocarcinoma cells. Cancer Sci, 96, 365-71. https://doi.org/10.1111/j.1349-7006.2005.00058.x
  16. Kim YH, Chung HC, Kang WK, et al (2008). Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemother Pharmacol, 62, 263-70. https://doi.org/10.1007/s00280-007-0600-y
  17. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  18. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  19. Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  20. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-09.
  21. Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of $Yadanzi^{(R)}$ (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12. https://doi.org/10.7314/APJCP.2013.14.3.2009
  22. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  23. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  24. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  25. Martin M (2006). Clinical experience with pemetrexed in breast cancer. Semin Oncol, 33, S15-8. https://doi.org/10.1053/j.seminoncol.2006.08.003
  26. Ohtsu A (2008). Chemotherapy for metastatic gastric cancer:past, present, and future. J Gastroenterol, 43, 256-64. https://doi.org/10.1007/s00535-008-2177-6
  27. Parkin DM, Bray F, Ferlay J et al (2005), Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  28. Parkin DM, Bray FI, Devesa SS (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 37, S4-66.
  29. Paz Ares.LG, de Marinis.F, Dediu.M, et al (2011). PARAMOUNT: phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. J Clin Oncol, 29 (suppl; abstr CRA7510).
  30. Paz-Ares.L, de Marinis.F, Dediu.M, et al (2012). Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol, 30 (suppl; abstr LBA7507).
  31. Pozzo C, Barone C (2008). Is there an optimal chemotherapy regimen for the treatment of advanced lung adenocarcinoma that will provide a platform for the introduction of new bio-logical agents? Oncologist, 13, 794-806. https://doi.org/10.1634/theoncologist.2008-0082
  32. Rollins KD, Lindley C (2005). Pemetrexed: a multitargeted antifolate. Clin Ther, 27, 1343-82. https://doi.org/10.1016/j.clinthera.2005.09.010
  33. Ross P, Nicolson M, Cunningham D, et al (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 20, 1996-2004. https://doi.org/10.1200/JCO.2002.08.105
  34. Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  35. Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev, 14, 149-52. https://doi.org/10.7314/APJCP.2013.14.1.149
  36. Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev,14(1):149-52. https://doi.org/10.7314/APJCP.2013.14.1.149
  37. Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 3:CD004064.
  38. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  39. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  40. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  41. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced lung adenocarcinoma cases. Asian Pac J Cancer Prev, 12, 985-7.
  42. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  43. Xu X, Wang L, Xu HQ, Huang XE, et al (2013). Clinical comparison between paclitaxel liposome ($Lipusu^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4. https://doi.org/10.7314/APJCP.2013.14.4.2591
  44. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  45. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  46. Yin HT, Tian QZ, Guan L,n vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6. https://doi.org/10.7314/APJCP.2013.14.3.1703
  47. Yin HT, Zhang DG, Wu XL, Huang XE, Chen G (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12. https://doi.org/10.7314/APJCP.2013.14.1.409
  48. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  49. Zhan YP, Huang XE, Cao J, Clinical study on safety and efficacy of Qinin (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6. https://doi.org/10.7314/APJCP.2012.13.9.4773
  50. Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of Kanglaite (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 5319-21. https://doi.org/10.7314/APJCP.2012.13.10.5319
  51. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  52. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  53. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

Cited by

  1. Clinical Study on Safety of Cantharidin Sodium and Shenmai Injection Combined with Chemotherapy in Treating Patients with Breast Cancer Postoperatively vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5597
  2. A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5941
  3. Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5945
  4. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  5. Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2511
  6. Lymphocyte Subgroups and their Surface Receptors NKG2D and NKG2A in Patients with Non-small Cell Lung Cancer vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2685
  7. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  8. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  9. Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647